Rethinking logistics, the key barrier to scaling cell and gene therapies

Personalized cell and gene therapies offer a beacon of hope to patients in need and vast financial prospects for emerging companies in the pharmaceutical industry. Because of their high cost of development, batch size of one, and complex shipping requirements, most remain boutique treatments, prized – and costly – options of last resort. It’s why companies stretch every dollar to push their therapeutics through clinical trials, going as far as to charter planes to deliver each dose of bespoke therapeutic to its patient.  

But the hard truth is that, as life-changing as these treatments may be, to scale to thousands of patients and survive on the market, they’ll need to break out of the boutique. This will require rethinking their supply chain and logistics.

Complete the form below to download the article.

Explore more from CSafe
Niall Prendiville Joins CSafe as Chief Product Officer to Drive Continued Growth in Innovation Across the Product Portfolio
Niall Prendiville Joins CSafe as Chief Product Officer to Drive Continued Growth in Innovation Across the Product Portfolio

Read More

Scaling Cell and Gene Therapy Logistics
For CGTs to reach their full potential and achieve global accessibility, scalable logistics systems are vital. This article delves into the challenges and innovative solutions shaping the scalability of CGT logistics.

Read More

Contact Us
We’re here to support you 24/7. Connect with our world-class customer service team, ready to assist with any questions or needs.